Proteomics International Laboratories Ltd
Company Profile
Business description
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.
Contact
6 Verdun Street
QEII Medical Centre, QQ Block
Nedlands
PerthWA6009
AUST: +61 893891992
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
funds
Proteomics set for growth, says Kardinia
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,820.30 | 6.40 | -0.07% |
CAC 40 | 7,829.29 | 72.96 | -0.92% |
DAX 40 | 24,255.31 | 201.50 | -0.82% |
Dow JONES (US) | 44,371.51 | 279.13 | -0.63% |
FTSE 100 | 8,941.12 | 34.54 | -0.38% |
HKSE | 24,139.57 | 111.20 | 0.46% |
NASDAQ | 20,585.53 | 45.14 | -0.22% |
Nikkei 225 | 39,569.68 | 76.68 | -0.19% |
NZX 50 Index | 12,686.68 | 73.52 | -0.58% |
S&P 500 | 6,259.75 | 20.71 | -0.33% |
S&P/ASX 200 | 8,580.10 | 9.10 | -0.11% |
SSE Composite Index | 3,510.18 | 0.50 | 0.01% |